Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 902, Issue , 2012, Pages 16-26

  Roche, Sandra ^a   Sewell, Louise ^a   Meiller, Justine ^a   Pedersen, Kasper ^a   Rajpal, Rajesh ^a,b   O'Gorman, Peter ^b   Clynes, Martin ^a   O'Connor, Robert ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cell culture; Compliance; LC MS MS; LLE; Multiple myeloma; Stability; Thalidomide; Thalidomide pharmacokinetics

Indexed keywords

COMPLIANCE; LC-MS/MS; LLE; MULTIPLE MYELOMA; THALIDOMIDE;

CELL CULTURE; CELLS; CONVERGENCE OF NUMERICAL METHODS; ELECTROSPRAY IONIZATION; FORMIC ACID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; SEPARATION;

BODY FLUIDS;

ACETONITRILE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FORMIC ACID; LABETALOL; MELPHALAN; PHENACETIN; PHTHALIMIDE; PREDNISONE; PRODIGY C 18; REAGENT; THALIDOMIDE; UMBELLIFERONE; UNCLASSIFIED DRUG; VINCRISTINE; WATER;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STABILITY; ELUTION; FLOW RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; LOW DRUG DOSE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; MULTIREACTION MONITORING; PRIORITY JOURNAL; REACTION ANALYSIS; SENSITIVITY AND SPECIFICITY; SERUM; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CELL EXTRACTS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA; DRUG STABILITY; HUMANS; LIQUID-LIQUID EXTRACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THALIDOMIDE;

EID: 84864078971     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.06.008     Document Type: Article

References (46)

1. Bartlett J.B., Dredge K., Dalgleish A.G. Nat. Rev. Cancer 2004, 4:314.
2. McBride W.G. Lancet 1961, 278:1358.
3. Lenz W., Pfeiffer R.A., Kosenow W., Hayman D.J. Lancet 1962, 279:45.
4. Sheskin J. Clin. Pharmacol. Therap. 1965, 303-306.
5. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J., Siegel D., Crowley J., Barlogie B. N. Engl. J. Med. 1999, 341:1565.
6. Cavo M., Zamagni E., Tosi P., Tacchetti P., Cellini C., Cangini D., de Vivo A., Testoni N., Nicci C., Terragna C., Grafone T., Perrone G., Ceccolini M., Tura S., Baccarani M. Blood 2005, 106:35.
7. Rajkumar S.V., Blood E., Vesole D., Fonseca R., Greipp P.R. J. Clin. Oncol. 2006, 24:431.
8. Zeldis J.B., Williams B.A., Thomas S.D., Elsayed M.E. Clin. Ther. 1999, 21:319.
9. Mateos M.-V. Cancer Treat. Rev. 2010, 36:S24.
10. Sung B., Kunnumakkara A.B., Sethi G., Anand P., Guha S., Aggarwal B.B. Mol. Cancer Therap. 2009, 8:959.
11. Keller M., Sollberger G., Beer H.-D. J. Immunol. 2009, 183:5593.
12. Haque A., Stewart J.T. J. Liq. Chromatogr. Relat. Technol. 1998, 21:2151.
13. Kenyon B.M., Browne F., D'Amato R.J. Exp. Eye Res. 1997, 64:971.
14. Reist M., Carrupt P.-A., Francotte E., Testa B. Chem. Res. Toxicol. 1998, 11:1521.
15. Eriksson T., Bjöurkman S., Roth B., Fyge Å., Höuglund P. Chirality 1995, 7:44.
16. Teo S.K., Chandula R.S., Harden J.L., Stirling D.I., Thomas S.D. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2002, 767:145.
17. Toraño J.S., Verbon A., Guchelaar H.J. J. Chromatogr. B: Biomed. Sci. Appl. 1999, 734:203.
18. Saccomanni G., Turini V., Manera C., Placanica G., Salè E.O., Jemos C., Giorgi M., Macchia M. J. Pharm. Biomed. Anal. 2008, 48:447.
19. Yang X., Hu Z., Chan S.Y., Ho P.C., Chan E., Duan W., Goh B.C., Zhou S. J. Pharm. Biomed. Anal. 2005, 39:299.
20. Zhou S., Li Y., Kestell P., Paxton J.W. J. Chromatogr. B 2003, 785:165.
21. Murphy-Poulton S.F., Boyle F., Gu X.Q., Mather L.E. J. Chromatogr. B 2006, 831:48.
22. Simmons B.R., Lush R.M., Figg W.D. Anal. Chim. Acta 1997, 339:91.
23. Delon A., Favreliere S., Couet W., Courtois P.H., Bouquet S. J. Liq. Chromatogr. 1995, 18:297.
24. Eriksson T., Bjorkman S., Roth B., Fyge A., Hoglund P. Chirality 1995, 7:44.
25. McBride S., Meleady P., Baird A., Dinsdale D., Clynes M. Tumour Biol. 1998, 19:88.
26. Duffy C.P., Elliott C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary I.M., Kavanagh K., Verhaegen S., O'Loughlin C.M., NicAmhlaoibh R., Clynes M. Eur. J. Cancer 1998, 34:1250.
27. Roche S., McMahon G., Clynes M., O'Connor R. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:3982.
28. Wieling J. Chromatographia 2002, 55:S107.
29. Tohnya T.M., Hwang K., Lepper E.R., Fine H.A., Dahut W.L., Venitz J., Sparreboom A., Figg W.D. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 811:135.
30. Eriksson T., Bjorkman S., Fyge A., Ekberg H. J. Chromatogr. 1992, 582:211.
31. Zirrolli J.A., Bradshaw E.L., Long M.E., Gustafson D.L. J. Pharm. Biomed. Anal. 2005, 39:705.
32. Ermer J. J. Pharm. Biomed. Anal. 2001, 24:755.
33. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
34. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., Spector S. J. Pharm. Sci. 1992, 81:309.
35. Franks M.E., Macpherson G.R., Figg W.D. Lancet 2004, 363:1802.
36. Kaya H., Peressini B., Jawed I., Martincic D., Elaimy A., Lamoreaux W., Fairbanks R., Weeks K., Lee C. Int. J. Hematol. 2012, 95:64.
37. Fried L.P., Bandeen-Roche K., Kasper J.D., Guralnik J.M. J. Clin. Epidemiol. 1999, 52:27.
38. Eriksson T., Björkman S., Höglund P. Eur. J. Clin. Pharmacol. 2001, 57:365.
39. Figg W.D., Raje S., Bauer K.S., Tompkins A., Venzon D., Bergan R., Chen A., Hamilton M., Pluda J., Reed E. J. Pharm. Sci. 1999, 88:121.
40. van Rhee F., Dhodapkar M., Shaughnessy J.D., Anaissie E., Siegel D., Hoering A., Zeldis J., Jenkins B., Singhal S., Mehta J., Crowley J., Jagannath S., Barlogie B. Blood 2008, 112:1035.
41. Dimopoulos M.A., Richardson P.G., Brandenburg N., Yu Z., Weber D.M., Niesvizky R., Morgan G.J. Blood 2012, 119:2764.
42. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm250606.htm.
43. Eriksson T., Bjorkman S., Lyon A.W., Raisys V.A. Clin. Chem. 1997, 43:1094.
44. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. J. Exp. Med. 1991, 173:699.
45. Deng L., Ding W., Granstein R.D. J. Invest. Dermatol. 2003, 121:1060.
46. Lokensgard J.R., Hu S., van Fenema E.M., Sheng W.S., Peterson P.K. J. Infect. Dis. 2000, 182:983.